메뉴 건너뛰기
JAMA - Journal of the American Medical Association
Volumn 315, Issue 19, 2016, Pages 2117-2118
Which oral anticoagulant for atrial fibrillation?
[No Author Info available]
Author keywords

[No Author keywords available]
Indexed keywords

ANDEXANET ALFA; ANTICOAGULANT AGENT; APIXABAN; CREATININE; DABIGATRAN ETEXILATE; EDOXABAN; FRESH FROZEN PLASMA; IDARUCIZUMAB; PROTHROMBIN COMPLEX; RIVAROXABAN; VITAMIN K GROUP; WARFARIN;
EID: 84969242764     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2016.4917     Document Type: Short Survey
Times cited : (1)
References (10)
  • 1
    • 34347394385 scopus 로고    scopus 로고
    • Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation
    • Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857-867.
    • (2007) Ann Intern Med , vol.146 , Issue.12 , pp. 857-867
    • Hart, R.G.1    Pearce, L.A.2    Aguilar, M.I.3
  • 2
    • 84879754339 scopus 로고    scopus 로고
    • Kcentra: a 4-factor prothrombin complex concentrate for reversal of warfarin anticoagulation
    • Kcentra: a 4-factor prothrombin complex concentrate for reversal of warfarin anticoagulation. Med Lett Drugs Ther. 2013;55 (1420):53-54.
    • (2013) Med Lett Drugs Ther , vol.55 , Issue.1420 , pp. 53-54
  • 3
    • 70349306707 scopus 로고    scopus 로고
    • RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation
    • Connolly SJ, Ezekowitz MD, Yusuf S, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-1151.
    • (2009) N Engl J Med , vol.361 , Issue.12 , pp. 1139-1151
    • Connolly, S.J.1    Ezekowitz, M.D.2    Yusuf, S.3
  • 4
    • 80052592404 scopus 로고    scopus 로고
    • ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
    • Patel MR, Mahaffey KW, Garg J, et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10):883-891.
    • (2011) N Engl J Med , vol.365 , Issue.10 , pp. 883-891
    • Patel, M.R.1    Mahaffey, K.W.2    Garg, J.3
  • 5
    • 80052825103 scopus 로고    scopus 로고
    • ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation
    • Granger CB, Alexander JH, McMurray JJ, et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-992.
    • (2011) N Engl J Med , vol.365 , Issue.11 , pp. 981-992
    • Granger, C.B.1    Alexander, J.H.2    McMurray, J.J.3
  • 6
    • 84888362796 scopus 로고    scopus 로고
    • ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation
    • Giugliano RP, Ruff CT, Braunwald E, et al; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093-2104.
    • (2013) N Engl J Med , vol.369 , Issue.22 , pp. 2093-2104
    • Giugliano, R.P.1    Ruff, C.T.2    Braunwald, E.3
  • 7
    • 84969274208 scopus 로고    scopus 로고
    • Accessed March 31, 2016 Food U.S. Drug Administration. FDA draft briefing document for the Cardiovascular and Renal Drugs Advisory Committee on October 30 NDA 206316
    • US Food and Drug Administration. FDA draft briefing document for the Cardiovascular and Renal Drugs Advisory Committee on October 30, 2014: NDA 206316. http://www.fda.gov /downloads/AdvisoryCommittees /CommitteesMeetingMaterials/Drugs /CardiovascularandRenalDrugsAdvisoryCommittee /UCM420704.pdf. Accessed March 31, 2016.
    • (2014)
  • 8
    • 84947775242 scopus 로고    scopus 로고
    • Idarucizumab (Praxbind)-an antidote for dabigatran
    • Idarucizumab (Praxbind)-an antidote for dabigatran. Med Lett Drugs Ther. 2015;57(1482): 157-158.
    • (2015) Med Lett Drugs Ther , vol.57 , Issue.1482 , pp. 157-158
  • 9
    • 84950127054 scopus 로고    scopus 로고
    • Andexanet alfa for the reversal of factor Xa inhibitor activity
    • Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med.2015;373(25):2413-2424.
    • (2015) N Engl J Med , vol.373 , Issue.25 , pp. 2413-2424
    • Siegal, D.M.1    Curnutte, J.T.2    Connolly, S.J.3
  • 10
    • 84878301573 scopus 로고    scopus 로고
    • Pharmacologic interventions for reversing the effects of oral anticoagulants
    • Kalus JS. Pharmacologic interventions for reversing the effects of oral anticoagulants. Am J Health Syst Pharm. 2013;70(10)(suppl 1):S12-S21.
    • (2013) Am J Health Syst Pharm , vol.70 , Issue.10 , pp. S12-S21
    • Kalus, J.S.1

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.